FOXO4-DRI is a metabolic & longevity research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
FOXO4-DRI is a D-retro-inverso (DRI) peptidomimetic based on a domain of the FOXO4 transcription factor — specifically the region that interacts with p53 in senescent cells. The DRI modification inverts the amino acid sequence and substitutes D-amino acids for L-amino acids throughout, producing a peptide that is highly resistant to proteolytic degradation in biological media while retaining the ability to penetrate cells and interact with its protein target. The compound was identified in the context of senescent cell biology and has become a research tool for studying targeted elimination of senescent cells — a cellular phenotype associated with aging and age-related tissue dysfunction.
The biological mechanism proposed for FOXO4-DRI centers on disrupting the FOXO4-p53 interaction in senescent cells. In senescent cells — unlike normal proliferating or quiescent cells — FOXO4 is reported to bind p53 and retain it in the nucleus, suppressing the p53-dependent apoptotic pathway that would otherwise eliminate the cell. FOXO4-DRI is hypothesized to competitively disrupt this interaction, releasing p53 from FOXO4 retention and restoring apoptotic signaling specifically in senescent cells. This selective mechanism — exploiting a senescence-specific FOXO4 activity — is the key feature distinguishing it from broadly cytotoxic approaches in senolytic research.
PeptidesFromChina.co supplies FOXO4-DRI as a lyophilized powder at 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis accompanies every batch. All products are for laboratory research use only and are not for human consumption.
| Chemical Class | D-retro-inverso peptidomimetic (DRI peptide) |
|---|---|
| Synonyms | FOXO4-DRI, FOXO4-p53 interfering peptide |
| Amino Acids | 18 (D-amino acid, retro-inverso sequence) |
| Molecular Weight | ~2448 Da |
| Research Areas | Senolytic biology, senescent cell elimination, p53 signaling, FOXO4-p53 interaction, aging models |
| Key Target | FOXO4-p53 protein-protein interaction in senescent cells |
| Form | Lyophilized powder |
| Storage | −20°C long-term; 2-8°C aqueous (short-term) |
| Sequence | D-retro-inverso 18-aa BH3 domain peptidomimetic (sequence available on COA) |
| CAS Number | Available on COA |
| Molecular Formula | N/A — D-retro-inverso peptidomimetic, see COA |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| FOXO4-DRI | 10 mg | 10 vials | ≥98% | In Stock | $400.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Assay"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Manufacturer COA. Documentation is available for every batch sold.
FOXO4-DRI is a primary research tool for studying FOXO4-p53-mediated senescent cell survival. Research has examined whether disrupting this interaction is sufficient to induce apoptosis selectively in senescent versus non-senescent cell populations. In vitro studies using senescent fibroblast and epithelial cell models have assessed apoptotic induction markers (cleaved caspase-3, PARP cleavage, Annexin V) following FOXO4-DRI treatment, with selectivity comparisons to normal cycling cells.
Preclinical studies in naturally aged and accelerated aging (e.g., doxorubicin-treated) rodent models have examined FOXO4-DRI administration in the context of senescent cell clearance. Research outcomes have included histological assessments of p16-positive and p21-positive senescent cell burden in tissues, along with functional endpoints such as tissue inflammation markers, fur density and appearance, and renal function — as used in the original Nature paper characterizing the compound.
The D-retro-inverso modification is a tool for generating metabolically stable peptidomimetics that preserve protein-binding geometry while resisting proteolytic degradation. FOXO4-DRI is a well-characterized example of this approach and is used in structural biology and pharmacology research to study how DRI modifications affect target affinity, cell penetration, and selectivity compared to the native L-amino acid peptide sequence.
FOXO4-DRI targets a specific FOXO4-p53 protein interaction proposed to be upregulated in senescent cells. Navitoclax inhibits Bcl-2 family anti-apoptotic proteins, and dasatinib/quercetin targets multiple senescence-associated pathways. FOXO4-DRI's hypothesized mechanism is more targeted to a senescence-specific protein interaction, while other senolytics typically have broader anti-apoptotic targets. Research comparing selectivity and tissue specificity across these approaches is an active area.
D-amino acids are not recognized by most endogenous proteases, which act on L-amino acid peptide bonds. The retro-inverso configuration additionally preserves side chain spatial orientation relative to the native sequence, maintaining target-binding geometry while dramatically improving proteolytic stability. This combination makes FOXO4-DRI a suitable cell-penetrating tool compound for intracellular target research.
FOXO4-DRI is synthesized to 99%+ purity, verified by HPLC and Mass Spectrometry. Certificate of Analysis from the manufacturing facility is included with every batch.
Lyophilized FOXO4-DRI should be stored at −20°C, protected from moisture and light. Reconstituted solutions should be kept at 2-8°C and used within 1-2 weeks.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.